TD Asset Management Inc Raises Holdings in Natera, Inc. (NASDAQ:NTRA)

TD Asset Management Inc grew its position in shares of Natera, Inc. (NASDAQ:NTRA) by 18.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 104,546 shares of the medical research company’s stock after buying an additional 16,378 shares during the period. TD Asset Management Inc owned 0.08% of Natera worth $14,784,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in NTRA. Fulton Bank N.A. raised its stake in shares of Natera by 2.0% during the 1st quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company’s stock valued at $516,000 after purchasing an additional 71 shares during the period. QRG Capital Management Inc. raised its stake in shares of Natera by 1.5% during the 1st quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company’s stock valued at $766,000 after purchasing an additional 81 shares during the period. Bridges Investment Management Inc. raised its stake in shares of Natera by 5.5% during the 1st quarter. Bridges Investment Management Inc. now owns 1,676 shares of the medical research company’s stock valued at $237,000 after purchasing an additional 87 shares during the period. Colonial Trust Co SC raised its stake in shares of Natera by 7.8% during the 4th quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company’s stock valued at $210,000 after purchasing an additional 96 shares during the period. Finally, Silvercrest Asset Management Group LLC raised its stake in shares of Natera by 3.6% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 2,812 shares of the medical research company’s stock valued at $445,000 after purchasing an additional 98 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling

In related news, CFO Michael Burkes Brophy sold 3,045 shares of the stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total transaction of $418,383.00. Following the completion of the sale, the chief financial officer directly owned 65,430 shares in the company, valued at $8,990,082. This represents a 4.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Steven Leonard Chapman sold 1,622 shares of the stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $139.29, for a total value of $225,928.38. Following the sale, the chief executive officer owned 175,492 shares of the company’s stock, valued at $24,444,280.68. This represents a 0.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,844 shares of company stock valued at $6,632,123. 7.60% of the stock is owned by insiders.

Natera Price Performance

Shares of NTRA stock opened at $140.96 on Thursday. The stock has a market capitalization of $19.25 billion, a PE ratio of -95.89 and a beta of 1.73. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00. The business has a 50-day moving average of $158.12 and a 200 day moving average of $156.45.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.09. The company had revenue of $501.83 million during the quarter, compared to analysts’ expectations of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. Natera’s quarterly revenue was up 36.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.56) EPS. Analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Ratings Changes

NTRA has been the topic of a number of analyst reports. Wall Street Zen lowered Natera from a “hold” rating to a “sell” rating in a research note on Saturday, May 17th. Evercore ISI upgraded Natera to a “strong-buy” rating and set a $170.00 price objective on the stock in a research note on Monday. Barclays upped their target price on Natera from $160.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday, May 9th. UBS Group upped their target price on Natera from $211.00 to $218.00 and gave the stock a “buy” rating in a research note on Friday, May 9th. Finally, Piper Sandler upped their target price on Natera from $205.00 to $210.00 and gave the stock an “overweight” rating in a research note on Thursday, May 15th. One analyst has rated the stock with a sell rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $183.76.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.